Universiteit Gent

Other

Henkel Ag & Company, Kgaa

Universiteit Hasselt

National Starch and Chemical Company Investment Holding Corporation

Henkel IP Holding Gmbh

Remon, Jean Paul

Universiteit Gent Laboratorium Voor Bromatologie Faculteit Farmaceutische Wetenschappen

Jean Paul Remon

Chris Vervaet

Paul B Foreman

Paul H Richardson

Glenn Verstraete

Dieter Ameye

John J Tsai

Catherine Callens

Jody Voorspoels

Jozef Antonius Willem Maria Corver

Thomas De Beer

Maxime Willems

Brecht Vanbillemont

Sam Corveleyn

Els Adriaens

Franciscus Joanna Jacobs

Karen Smeets

Paul A Altieri

Aleksandra Dukic

An-Sofie Stevens

Marleen Temmerman

Hans Verstraelen

Michelle Plusquin

Tom Artois

Bruno De Geest

Johan Grooten

Stefaan De Koker

Evy Corbanie

Wilhelmus Johannes Mathernus Landman

Johannes Hubertus Henricus Van Eck

A device for holding and monitoring a predetermined dose of a product during a freezing, drying and/or lyophilization process, includes a mold having a receptacle part for containing the predetermined dose of the product in direct contact with the receptacle part, a sensor, contacting the mold or integrated in the mold, for measuring a physical characteristic and/or quantity, and a transmitter for transmitting the measured characteristic and/or quantity in the form of a sensor signal to a control unit for controlling a heating and/or cooling element, integrated in the device, for heating and/or cooling a predetermined dose of product during a freezing, drying and/or lyophilization process, in the lyophilization process. The device relates in further aspects to a system and a method.

Freezing, drying and/or freeze-drying of product dose units

The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.

Oral dosage form

This invention relates to xanthohumol-based compositions, yielded in a hot-melt extrusion process (HME) using one or more water-soluble nutritionally and/or cosmetically acceptable thermoplastic polymers, such as selected from hydroxypropylmethyl-cellulose (HPMC), a vinylpyrrolidone-vinyl acetate copolymer, and combinations thereof. The present invention also relates to topical and oral formulations comprising such extruded xanthohumol-based compositions, as well as the use of one or more water-soluble nutritionally and/or cosmetically acceptable thermoplastic polymers in a hot-melt extrusion process of xanthohumol.

Xanthohumol-based compositions

The present invention in general relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one active ingredient and at least one dicarboxylic acid. It in particular relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one anthelmintic drug and at least one dicarboxylic acid. The invention further relates to uses, methods for use and methods for manufacturing the pharmaceutical suspension according to this invention.

Pharmaceutical nanosuspension

This disclosure relates to predicting the carcinogenicity of compounds. More in particular, this application discloses methods to detect whether a compound is a non-genotoxic carcinogen and methods to discriminate between genotoxic and non-genotoxic carcinogens based on in vivo stem cell proliferation patterns in flatworms.

Methods to detect non-genotoxic carcinogens using flatworms

The present invention in general relates to an intravaginal delivery system as well as uses thereof and methods for manufacturing and use of the same. In particular the present invention relates to an intravaginal delivery system for the controlled release of one or more organic acids, such as lactic acid; said intravaginal delivery system being characterized in that it comprises a combination of ethylene vinyl acetate (EVA) copolymers and carboxylic polymers, such as for example methacrylic acid-methacrylic ester copolymers.

Intravaginal delivery system

A pharmaceutical or veterinary granule composition in the form of a mixture consisting essentially of: (i) at least one drug classifiable as Class II or Class IV of the Biopharmaceutical Classification System, wherein said drug (i) constitutes from above about 20% to 50% by weight of the composition, said pharmaceutical or veterinary granule composition providing a drug release of at least 70% within 10 minutes in water, (ii) a first excipient being a maltodextrin representing from 40% by weight to 85% by weight of said composition, (iii) a wetting amount of a second excipient being a polyethylene glycol having a weight number molecular weight between 300 and 5,000, said second excipient comprising a solid fraction and a liquid fraction, and representing from 15% to 40% by weight of said composition, and optionally one or more pharma-ceutically acceptable fillers selected from the group consisting of hydrocolloids, glidants, lubricants, surfactants and diluents, wherein the weight ratio of said first excipient (ii) to said second excipient (iii) is in a range from 1:1 to 5:1.

Immediate release pharmaceutical granule compositions and a continuous process for making them

A pharmaceutical or veterinary granule composition in the form of a mixture consisting essentially of: (i) at least one drug classifiable as Class II or Class IV of the Biopharmaceutical Classification System, wherein said drug (i) constitutes from 0.5% to 20% by weight of the composition, and excipients, said pharmaceutical or veterinary granule composition providing a drug release of at least 70% within 10 minutes in water, (ii) a first excipient being a maltodextrin representing from 40% by weight to 80% by weight of said composition, (iii) a wetting amount of a second excipient being a polyethylene glycol having a weight number molecular weight between 300 and 5,000, said second excipient comprising a solid fraction and a liquid fraction, and representing from 15% to 40% by weight of said composition, and optionally one or more pharmaceutically acceptable fillers selected from the group consisting of hydrocolloids, glidants, lubricants, surfactants and diluents, wherein the weight ratio of said first excipient (ii) to said second excipient (iii) is in a range from 1:1 to 5:1.

This patent pertains to the use of debranched starch in the preparation of pharmaceutical pellets by extrusion spheronization. Such excipients are useful in any dry dosage form, including tablets and capsules, for either immediate or sustained release.

Use of debranched starch in extrusion-spheronization pharmaceutical pellets

The invention provides bioadhesive composition having increased bioadhesive properties, decreased irritation, and the capacity for higher drug loading. The compositions of the invention comprise intimate mixtures of a polysaccharide and a polycarboxylated polymer, and optionally also an absorption enhancer.

Bioadhesive composition

Biologically inactive cushioning beads comprise at least one compressible cushioning component consisting essentially of a microcrystalline hydrocarbon wax or a natural wax, the said wax being at least 30% by weight of the biologically inactive cushioning beads. Such beads are useful for making solid shaped articles containing biologically active ingredients by compression.

Cushioning wax beads for making solid shaped articles

This invention relates to a method of producing a bioadhesive composition comprising the steps of preparing a solution of a solvent and a polymer mixture wherein the polymer mixture comprises at least one natural or synthetic polycarboxylated polymer and at least one polysaccharide; drying the solution to form a solid; and heat treating the solid to effect cross-linking and to form the bioadhesive composition.

A beeswax mimetic substance is described which comprises or consists essentially of a synthetic or semisynthetic wax, in particular a microcrystalline wax. The wax preferably has a relatively narrow range of mean carbon chain length. An apiculture accessory using the wax and a method of operating beehives using the wax to reduce disease and pests in beehives is described.

Growing community of inventors

Melle, Belgium

Jean Paul Remon